Antitumor activity of Virulizin, a novel biological response modifier (BRM) in a panel of human pancreatic cancer and melanoma xenografts
To define the anticancer efficacy of Virulizin in vivo as a single agent or in combination with conventional drugs in human pancreatic tumor and melanoma xenografts. The therapeutic effect of Virulizin was evaluated in a series of human tumor xenografts in athymic nude mice. Virulizin had a high lev...
Gespeichert in:
| Veröffentlicht in: | Cancer chemotherapy and pharmacology 2003-03, Vol.51 (3), p.247-255 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 255 |
|---|---|
| container_issue | 3 |
| container_start_page | 247 |
| container_title | Cancer chemotherapy and pharmacology |
| container_volume | 51 |
| creator | NINGPING FENG HONGNAN JIN MING WANG CAIGAN DU WRIGHT, Jim A YOUNG, Aiping H |
| description | To define the anticancer efficacy of Virulizin in vivo as a single agent or in combination with conventional drugs in human pancreatic tumor and melanoma xenografts.
The therapeutic effect of Virulizin was evaluated in a series of human tumor xenografts in athymic nude mice.
Virulizin had a high level of antitumor activity against all the pancreatic tumors (BxPC-3, SU 86.86. and Mia-PaCa-2) and melanomas (C8161 and A2058), as indicated by suppression of tumor growth with an optimal T/C value of |
| doi_str_mv | 10.1007/s00280-002-0559-7 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_73117642</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>73117642</sourcerecordid><originalsourceid>FETCH-LOGICAL-c354t-3511f1fe16af1bd55b5b754838b31bff91c11a97cda078621041c4e1a3fc3d743</originalsourceid><addsrcrecordid>eNpdkd1q3DAQhUVoSTabPEBviii0tFA3GkuyvJdpaH4goVCa3ApZllIFW9pKdmjyBn3rzrILgd6MZuCbw9EcQt4A-wKMqZPCWN2yCmvFpFxVao8sQHCcWsFfkQXjQlRSMXFADkt5YIwJ4HyfHEDdSCmEWJC_p3EK0zymTI2dwmOYnmjy9C7keQjPIX6mhsb06AbahTSk-2DNQLMr6xSLo2Pqgw8u049ff9x8oiEivTYRadT4NY8mbkabnZmCpRZbZE3s6egGE9No6B8X0302fipH5LU3Q3HHu3dJbs-__Ty7rK6_X1ydnV5XlksxVVwCePAOGuOh66XsZKekaHnbcei8X4EFMCtle8NU29SAf7bCgeHe8l4JviQftrrrnH7Prkx6DMW6AQ25NBetOIBqRI3gu__AhzTniN50DehF1i1HCLaQzamU7Lxe5zCa_KSB6U1IehuSxqo3IaH-krzdCc_d6PqXjV0qCLzfAabgvX3Gw4XywommYawF_g-64JpO</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>213545283</pqid></control><display><type>article</type><title>Antitumor activity of Virulizin, a novel biological response modifier (BRM) in a panel of human pancreatic cancer and melanoma xenografts</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>NINGPING FENG ; HONGNAN JIN ; MING WANG ; CAIGAN DU ; WRIGHT, Jim A ; YOUNG, Aiping H</creator><creatorcontrib>NINGPING FENG ; HONGNAN JIN ; MING WANG ; CAIGAN DU ; WRIGHT, Jim A ; YOUNG, Aiping H</creatorcontrib><description>To define the anticancer efficacy of Virulizin in vivo as a single agent or in combination with conventional drugs in human pancreatic tumor and melanoma xenografts.
The therapeutic effect of Virulizin was evaluated in a series of human tumor xenografts in athymic nude mice.
Virulizin had a high level of antitumor activity against all the pancreatic tumors (BxPC-3, SU 86.86. and Mia-PaCa-2) and melanomas (C8161 and A2058), as indicated by suppression of tumor growth with an optimal T/C value of <or=40% when administered as a single agent. No significant changes in Virulizin antitumor activity were observed when different schedules (3 days/week vs 7 days/week) or routes of administration (i.p. vs i.m.) were used. In combination therapy, Virulizin significantly enhanced the antitumor activity of gemcitabine and 5-fluorouracil against pancreatic tumors and of dacarbazine against metastatic melanomas, as reflected by a further decrease in tumor growth as compared to tumors in animals treated with the conventional drugs alone.
These studies suggest that Virulizin effectively inhibits the growth of solid human pancreatic tumors and melanomas in the xenograft model.</description><identifier>ISSN: 0344-5704</identifier><identifier>EISSN: 1432-0843</identifier><identifier>DOI: 10.1007/s00280-002-0559-7</identifier><identifier>PMID: 12655444</identifier><identifier>CODEN: CCPHDZ</identifier><language>eng</language><publisher>Berlin: Springer</publisher><subject>Adjuvants, Immunologic - administration & dosage ; Adjuvants, Immunologic - pharmacology ; Animals ; Antineoplastic agents ; Bile ; Biological and medical sciences ; Chemotherapy ; Female ; Humans ; Injections, Intramuscular ; Injections, Intraperitoneal ; Medical sciences ; Melanoma - drug therapy ; Melanoma - veterinary ; Mice ; Mice, Nude ; Neoplasms, Experimental ; Pancreatic cancer ; Pancreatic Neoplasms - drug therapy ; Pancreatic Neoplasms - veterinary ; Pharmacology. Drug treatments ; Skin Neoplasms - drug therapy ; Skin Neoplasms - veterinary ; Tissue Extracts ; Transplantation, Heterologous</subject><ispartof>Cancer chemotherapy and pharmacology, 2003-03, Vol.51 (3), p.247-255</ispartof><rights>2003 INIST-CNRS</rights><rights>Copyright Springer-Verlag 2003</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c354t-3511f1fe16af1bd55b5b754838b31bff91c11a97cda078621041c4e1a3fc3d743</citedby><cites>FETCH-LOGICAL-c354t-3511f1fe16af1bd55b5b754838b31bff91c11a97cda078621041c4e1a3fc3d743</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=14660081$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12655444$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>NINGPING FENG</creatorcontrib><creatorcontrib>HONGNAN JIN</creatorcontrib><creatorcontrib>MING WANG</creatorcontrib><creatorcontrib>CAIGAN DU</creatorcontrib><creatorcontrib>WRIGHT, Jim A</creatorcontrib><creatorcontrib>YOUNG, Aiping H</creatorcontrib><title>Antitumor activity of Virulizin, a novel biological response modifier (BRM) in a panel of human pancreatic cancer and melanoma xenografts</title><title>Cancer chemotherapy and pharmacology</title><addtitle>Cancer Chemother Pharmacol</addtitle><description>To define the anticancer efficacy of Virulizin in vivo as a single agent or in combination with conventional drugs in human pancreatic tumor and melanoma xenografts.
The therapeutic effect of Virulizin was evaluated in a series of human tumor xenografts in athymic nude mice.
Virulizin had a high level of antitumor activity against all the pancreatic tumors (BxPC-3, SU 86.86. and Mia-PaCa-2) and melanomas (C8161 and A2058), as indicated by suppression of tumor growth with an optimal T/C value of <or=40% when administered as a single agent. No significant changes in Virulizin antitumor activity were observed when different schedules (3 days/week vs 7 days/week) or routes of administration (i.p. vs i.m.) were used. In combination therapy, Virulizin significantly enhanced the antitumor activity of gemcitabine and 5-fluorouracil against pancreatic tumors and of dacarbazine against metastatic melanomas, as reflected by a further decrease in tumor growth as compared to tumors in animals treated with the conventional drugs alone.
These studies suggest that Virulizin effectively inhibits the growth of solid human pancreatic tumors and melanomas in the xenograft model.</description><subject>Adjuvants, Immunologic - administration & dosage</subject><subject>Adjuvants, Immunologic - pharmacology</subject><subject>Animals</subject><subject>Antineoplastic agents</subject><subject>Bile</subject><subject>Biological and medical sciences</subject><subject>Chemotherapy</subject><subject>Female</subject><subject>Humans</subject><subject>Injections, Intramuscular</subject><subject>Injections, Intraperitoneal</subject><subject>Medical sciences</subject><subject>Melanoma - drug therapy</subject><subject>Melanoma - veterinary</subject><subject>Mice</subject><subject>Mice, Nude</subject><subject>Neoplasms, Experimental</subject><subject>Pancreatic cancer</subject><subject>Pancreatic Neoplasms - drug therapy</subject><subject>Pancreatic Neoplasms - veterinary</subject><subject>Pharmacology. Drug treatments</subject><subject>Skin Neoplasms - drug therapy</subject><subject>Skin Neoplasms - veterinary</subject><subject>Tissue Extracts</subject><subject>Transplantation, Heterologous</subject><issn>0344-5704</issn><issn>1432-0843</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNpdkd1q3DAQhUVoSTabPEBviii0tFA3GkuyvJdpaH4goVCa3ApZllIFW9pKdmjyBn3rzrILgd6MZuCbw9EcQt4A-wKMqZPCWN2yCmvFpFxVao8sQHCcWsFfkQXjQlRSMXFADkt5YIwJ4HyfHEDdSCmEWJC_p3EK0zymTI2dwmOYnmjy9C7keQjPIX6mhsb06AbahTSk-2DNQLMr6xSLo2Pqgw8u049ff9x8oiEivTYRadT4NY8mbkabnZmCpRZbZE3s6egGE9No6B8X0302fipH5LU3Q3HHu3dJbs-__Ty7rK6_X1ydnV5XlksxVVwCePAOGuOh66XsZKekaHnbcei8X4EFMCtle8NU29SAf7bCgeHe8l4JviQftrrrnH7Prkx6DMW6AQ25NBetOIBqRI3gu__AhzTniN50DehF1i1HCLaQzamU7Lxe5zCa_KSB6U1IehuSxqo3IaH-krzdCc_d6PqXjV0qCLzfAabgvX3Gw4XywommYawF_g-64JpO</recordid><startdate>20030301</startdate><enddate>20030301</enddate><creator>NINGPING FENG</creator><creator>HONGNAN JIN</creator><creator>MING WANG</creator><creator>CAIGAN DU</creator><creator>WRIGHT, Jim A</creator><creator>YOUNG, Aiping H</creator><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20030301</creationdate><title>Antitumor activity of Virulizin, a novel biological response modifier (BRM) in a panel of human pancreatic cancer and melanoma xenografts</title><author>NINGPING FENG ; HONGNAN JIN ; MING WANG ; CAIGAN DU ; WRIGHT, Jim A ; YOUNG, Aiping H</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c354t-3511f1fe16af1bd55b5b754838b31bff91c11a97cda078621041c4e1a3fc3d743</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Adjuvants, Immunologic - administration & dosage</topic><topic>Adjuvants, Immunologic - pharmacology</topic><topic>Animals</topic><topic>Antineoplastic agents</topic><topic>Bile</topic><topic>Biological and medical sciences</topic><topic>Chemotherapy</topic><topic>Female</topic><topic>Humans</topic><topic>Injections, Intramuscular</topic><topic>Injections, Intraperitoneal</topic><topic>Medical sciences</topic><topic>Melanoma - drug therapy</topic><topic>Melanoma - veterinary</topic><topic>Mice</topic><topic>Mice, Nude</topic><topic>Neoplasms, Experimental</topic><topic>Pancreatic cancer</topic><topic>Pancreatic Neoplasms - drug therapy</topic><topic>Pancreatic Neoplasms - veterinary</topic><topic>Pharmacology. Drug treatments</topic><topic>Skin Neoplasms - drug therapy</topic><topic>Skin Neoplasms - veterinary</topic><topic>Tissue Extracts</topic><topic>Transplantation, Heterologous</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>NINGPING FENG</creatorcontrib><creatorcontrib>HONGNAN JIN</creatorcontrib><creatorcontrib>MING WANG</creatorcontrib><creatorcontrib>CAIGAN DU</creatorcontrib><creatorcontrib>WRIGHT, Jim A</creatorcontrib><creatorcontrib>YOUNG, Aiping H</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Cancer chemotherapy and pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>NINGPING FENG</au><au>HONGNAN JIN</au><au>MING WANG</au><au>CAIGAN DU</au><au>WRIGHT, Jim A</au><au>YOUNG, Aiping H</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Antitumor activity of Virulizin, a novel biological response modifier (BRM) in a panel of human pancreatic cancer and melanoma xenografts</atitle><jtitle>Cancer chemotherapy and pharmacology</jtitle><addtitle>Cancer Chemother Pharmacol</addtitle><date>2003-03-01</date><risdate>2003</risdate><volume>51</volume><issue>3</issue><spage>247</spage><epage>255</epage><pages>247-255</pages><issn>0344-5704</issn><eissn>1432-0843</eissn><coden>CCPHDZ</coden><abstract>To define the anticancer efficacy of Virulizin in vivo as a single agent or in combination with conventional drugs in human pancreatic tumor and melanoma xenografts.
The therapeutic effect of Virulizin was evaluated in a series of human tumor xenografts in athymic nude mice.
Virulizin had a high level of antitumor activity against all the pancreatic tumors (BxPC-3, SU 86.86. and Mia-PaCa-2) and melanomas (C8161 and A2058), as indicated by suppression of tumor growth with an optimal T/C value of <or=40% when administered as a single agent. No significant changes in Virulizin antitumor activity were observed when different schedules (3 days/week vs 7 days/week) or routes of administration (i.p. vs i.m.) were used. In combination therapy, Virulizin significantly enhanced the antitumor activity of gemcitabine and 5-fluorouracil against pancreatic tumors and of dacarbazine against metastatic melanomas, as reflected by a further decrease in tumor growth as compared to tumors in animals treated with the conventional drugs alone.
These studies suggest that Virulizin effectively inhibits the growth of solid human pancreatic tumors and melanomas in the xenograft model.</abstract><cop>Berlin</cop><pub>Springer</pub><pmid>12655444</pmid><doi>10.1007/s00280-002-0559-7</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0344-5704 |
| ispartof | Cancer chemotherapy and pharmacology, 2003-03, Vol.51 (3), p.247-255 |
| issn | 0344-5704 1432-0843 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_73117642 |
| source | MEDLINE; Springer Nature - Complete Springer Journals |
| subjects | Adjuvants, Immunologic - administration & dosage Adjuvants, Immunologic - pharmacology Animals Antineoplastic agents Bile Biological and medical sciences Chemotherapy Female Humans Injections, Intramuscular Injections, Intraperitoneal Medical sciences Melanoma - drug therapy Melanoma - veterinary Mice Mice, Nude Neoplasms, Experimental Pancreatic cancer Pancreatic Neoplasms - drug therapy Pancreatic Neoplasms - veterinary Pharmacology. Drug treatments Skin Neoplasms - drug therapy Skin Neoplasms - veterinary Tissue Extracts Transplantation, Heterologous |
| title | Antitumor activity of Virulizin, a novel biological response modifier (BRM) in a panel of human pancreatic cancer and melanoma xenografts |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T11%3A51%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Antitumor%20activity%20of%20Virulizin,%20a%20novel%20biological%20response%20modifier%20(BRM)%20in%20a%20panel%20of%20human%20pancreatic%20cancer%20and%20melanoma%20xenografts&rft.jtitle=Cancer%20chemotherapy%20and%20pharmacology&rft.au=NINGPING%20FENG&rft.date=2003-03-01&rft.volume=51&rft.issue=3&rft.spage=247&rft.epage=255&rft.pages=247-255&rft.issn=0344-5704&rft.eissn=1432-0843&rft.coden=CCPHDZ&rft_id=info:doi/10.1007/s00280-002-0559-7&rft_dat=%3Cproquest_cross%3E73117642%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=213545283&rft_id=info:pmid/12655444&rfr_iscdi=true |